| abstract |
The invention relates to an imidazolidine derivative represented by the following general formula (1):n n wherein A and B mean individually an aromatic hydrocarbon group which may be substituted by 1-3 substituents selected from halogen atoms, C 1-4 alkyl groups, C 1-4 alkoxy groups, C 1-4 alkylenedioxy groups, a phenoxy group, a nitro group, a cyano group, a phenyl group, C 2-5 alkanoylamino groups, a carboxyl group which may be esterified with a C 1-4 alkyl or alkenyl group, carboxyalkyl groups which may be esterified with a C 1-4 alkyl or alkenyl group, carboxyalkyloxy groups which may be esterified with a C 1-4 alkyl or alkenyl group, N-alkylpiperazinylcarbonyl groups, N-alkylpiperazinylcarbonylalkyl groups, N-alkylpiperazinylcarbonylalkyloxy groups, and a morpholinocarbonyl group; X denotes a sulfonyl or carbonyl group; and Y stands for an oxygen or sulfur atom, a chymase inhibitor comprising the same as an active ingredient, and a medicine comprising the same as an active ingredient, typified by a prophylactic and therapeutic agent for a disease of the heart or circulatory system, which is caused by the abnormal acceleration of production of angiotensin II. |